Get the Stockscreener App
0.241
5.32%
-0.0144
Nkgen Biotech Inc stock is traded at $0.241, with a volume of 317.84K.
It is down -5.32% in the last 24 hours and down -39.55% over the past month.
NKGen Biotech Inc is a biotechnology company developing cell therapies for neurodegenerative and oncological diseases based on activated NK cells. NK cells are part of the human innate immune response system that can selectively identify and destroy abnormal or diseased cells. Its product candidates are based on a proprietary manufacturing and cryopreservation process that produces SuperNKTM (SNK) cells that have shown increased activity as compared to the starting population of NK cells, based on the results of in vitro experiments performed by NKMAX, as defined by parameters such as cytotoxicity, cytokine production and activating receptor expression. SNK cells can be produced in large quantities and cryopreserved while maintaining high levels of cytotoxicity.
See More
Previous Close:
$0.2554
Open:
$0.251
24h Volume:
317.84K
Relative Volume:
0.31
Market Cap:
$8.99M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-22.23%
1M Performance:
-39.55%
6M Performance:
-83.09%
1Y Performance:
-92.07%
1-Day Range:
$0.235
$0.2681
1-Week Range:
$0.235
$0.295
52-Week Range:
$0.2026
$4.06
Nkgen Biotech Inc Stock (NKGN) Company Profile
Name
Nkgen Biotech Inc
Sector
Industry
Phone
(949) 396-6830
Address
3001 DAIMLER ST,, SANTA ANA
Nkgen Biotech Inc Stock (NKGN) Latest News
NKGen Flat on Presentation of Alzheimer's Treatment - Baystreet.ca
NKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer's Disease at the 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference - The Manila Times
NKGen Biotech Presents Phase 1/2a Troculeucel Data in - GlobeNewswire
NKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference - StockTitan
Midday Stock Roundup: The Ensign Group Beats Q3 Expectations - Orange County Business Journal
NKGen Biotech avoids Nasdaq delisting with regained compliance - Investing.com India
Navigating NKGN Stock: NKGen Biotech Inc Journey - The InvestChronicle
Post-Trade Analysis: NKGen Biotech Inc (NKGN) Slides -6.54, Closing at 0.23 - The Dwinnex
NKGen Biotech Announces Upcoming Presentation at the 16th World Stroke Congress (WSC 2024) - The Manila Times
NKGen Biotech undergoes dilutive stock issuance By Investing.com - Investing.com Canada
NKGen Biotech undergoes dilutive stock issuance - Investing.com India
NKGN stock touches 52-week low at $0.35 amid market challenges - Investing.com Australia
NKGen Biotech Announces Poster Presentations at the 17th - GlobeNewswire
NKGen Biotech Announces Poster Presentations at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference - StockTitan
Market Watch Highlights: NKGen Biotech Inc (NKGN) Ends on an Upturn Note at 0.40 - The Dwinnex
NKGen Biotech directors resign after a year of service By Investing.com - Investing.com Australia
NKGen Biotech appoints new directors to its board By Investing.com - Investing.com South Africa
NKGen Biotech appoints new directors to its board - Investing.com India
NKGen Biotech Welcomes New Directors and Assigns Committees - TipRanks
NKGen Biotech directors resign after a year of service - Investing.com India
NKGen Biotech Announces Leadership Shuffle on Anniversary - TipRanks
NKGen Biotech faces potential Nasdaq delisting By Investing.com - Investing.com South Africa
NKGen Biotech faces potential Nasdaq delisting - Investing.com
Midday Stock Roundup: Indie Shares Down 5% - Orange County Business Journal
Analysts agree that Kenvue's Neutrogena needs a face-lift (KVUE) - Seeking Alpha
Nkarta Inc (NKTX)’s highs and lows: A closer look at its stock price fluctuations - US Post News
Top investors say Krystal Biotech Inc (KRYS) ticks everything they need - SETE News
Investor’s Delight: Krystal Biotech Inc (KRYS) Closes Weak at 184.17, Down -0.17 - The Dwinnex
Market Momentum Report: Nkarta Inc (NKTX)’s Negative Close at 5.21 - The Dwinnex
Raymond James Upgrades Nkarta Inc (NKTX) to a Strong buy from an Outperform - Knox Daily
70,000 Shares in Neurogene Inc. (NASDAQ:NGNE) Purchased by Integral Health Asset Management LLC - Defense World
Krystal Biotech, Inc. (KRYS): Promising Pipeline or Risky Gamble? - Insider Monkey
ASB Consultores LLC Trims Stock Holdings in PENN Entertainment, Inc. (NASDAQ:PENN) - Defense World
NKGen Biotech issues shares for debt conversion - Investing.com
What was NKGen Biotech Inc (NKGN)’s performance in the last session? - US Post News
NKGN stock touches 52-week low at $0.45 amid market challenges - Investing.com
NKGN’s Stock Market Adventure: -82.15% YTD Growth Amidst Volatility - The InvestChronicle
Market Momentum: NKGen Biotech Inc (NKGN) Registers a -34.09 Decrease, Closing at 0.49 - The Dwinnex
NKGen Biotech appeals Nasdaq delisting decision - Investing.com
NKGen Biotech faces Nasdaq delisting over market value - Investing.com India
A closer look at NKGN’s price-to-free cash flow ratio - US Post News
Selling Your Nano Nuclear Energy Inc. (NASDAQ: NNE) Stock? Here’s What You Need To Know - Stocks Register
NKGen Biotech’s Positive Phase 1 Clinical Data in Moderate - GlobeNewswire
NKGen Biotech’s Positive Phase 1 Clinical Data in Moderate Alzheimer’s Disease Advances Troculeucel into Phase 2 with First Patient Dosed in Phase 1/2a Trial - StockTitan
NKGen Biotech amends agreement, increases share consideration By Investing.com - Investing.com Australia
New Outlook On Intelligent Bio Solutions Inc - Stocks Register
NKGen Biotech amends agreement, increases share consideration - Investing.com
NKGen Biotech Expands Agreement Terms and Restructures COO Role - TipRanks
NKGen Biotech to Showcase at Global Investment Conference - TipRanks
Nkgen Biotech Inc Stock (NKGN) Financials Data
There is no financial data for Nkgen Biotech Inc (NKGN). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Nkgen Biotech Inc Stock (NKGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Song Paul Y. | Chief Executive Officer |
Dec 06 '23 |
Buy |
3.32 |
75 |
250 |
171,045 |
| Song Paul Y. | Chief Executive Officer |
Dec 04 '23 |
Buy |
3.07 |
163 |
500 |
170,864 |
| Song Paul Y. | Chief Executive Officer |
Dec 05 '23 |
Buy |
3.33 |
105 |
350 |
170,969 |
| Graf James A | Interim CFO |
Dec 04 '23 |
Buy |
3.19 |
450 |
1,436 |
693 |
| Graf James A | Interim CFO |
Dec 01 '23 |
Buy |
3.35 |
220 |
737 |
243 |
| Song Paul Y. | Chief Executive Officer |
Nov 27 '23 |
Buy |
2.88 |
244 |
701 |
170,701 |
| Graf James A | Interim CFO |
Nov 21 '23 |
Buy |
2.92 |
13 |
38 |
23 |
| Graf James A | Interim CFO |
Nov 20 '23 |
Buy |
2.94 |
10 |
29 |
10 |
| Song Paul Y. | Chief Executive Officer |
Nov 21 '23 |
Buy |
2.80 |
100 |
280 |
170,405 |
| Song Paul Y. | Chief Executive Officer |
Nov 22 '23 |
Buy |
2.85 |
53 |
150 |
170,458 |
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):